Rani Therapeutics, a clinical-stage biopharmaceutical company and developer of the RaniPill™ robotic pill, today announced that it has raised $69 million in a Series E financing, bringing the total funding to $211 million. BofA Securities acted as financial advisor to the company.

Rani Therapeutics has developed the RaniPill™ robotic pill, an oral biologics platform designed to replace injectable biologics. The RaniPill™ is a pain-free alternative for subcutaneous injections, eliminating one of the biggest obstacles to patient compliance. Rani has a strong patent position with more than 280 patents filed. The research and technology behind Rani Therapeutics came out of InCube Labs, a multi-disciplinary life sciences R&D lab focused on breakthrough medical innovations. Rani and InCube are founded by Mir Imran, a prolific medical inventor, entrepreneur, and investor.